Background: Retesting for Human epidermal growth factor receptor-2 (HER2) in post-neoadjuvant therapy resection is variable. and data is conflicting regarding the prognostic significance of changes in HER2 expression pre and post therapy. Methods: We identified 104 patients with localized HER2 IHC 3+ breast cancer who received neoadjuvant trastuzumab(T)/pertuzumab(P) containing chemot... https://www.spidertattooz.com/OPI-GelColor-The-Color-That-Keeps-On-Giving-0-5-oz-HPJ07-p22791/